Immunotherapy – new perspective in lung cancer

doi:10.5306/wjco.v11.i5.250

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8791)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

610

WORD

222

HTML

5577

Figures (1-1)

287

Tables (1-1)

239

Sum=6935

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

781

Download

1075

Sum=1856

May 24, 2020 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. May 24, 2020; 11(5): 250-259
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.250

Immunotherapy – new perspective in lung cancer

Fillipe Dantas Pinheiro, Adriano Fernandes Teixeira, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Maria Luísa Cordeiro Santos, Fabrício Freire de Melo

Fillipe Dantas Pinheiro, Adriano Fernandes Teixeira, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Maria Luísa Cordeiro Santos, Fabrício Freire de Melo, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil

Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

Conflict-of-interest statement: No potential conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Corresponding author: Fabrício Freire de Melo, PhD, Postdoctoral Fellow, Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros 58 Quadra 17 Lote 58, Vitória da Conquista 45029-094, Bahia, Brazil. freiremelo@yahoo.com.br

Received: December 29, 2019
Peer-review started: December 30, 2019
First decision: April 3, 2020
Revised: April 10, 2020
Accepted: April 23, 2020
Article in press: April 23, 2020
Published online: May 24, 2020

Core Tip

Core tip: Immunotherapy has represented a new hope in the treatment of lung cancer. Improvements in global survival curves in metastatic disease and in local advanced disease have been observed with that therapeutic modality. However, some side effects that are unusual in standard chemotherapy have been frequently observed in immunotherapy, and they require special clinical support. This review aims to discuss some aspects regarding immunotherapy in non-small cell lung cancer and the perspectives about the use of this treatment in the adjuvant scenario and in small cell lung cancer.